Varian cancer treatment system cleared in US:
This article was originally published in Clinica
VariSource, Varian Associates' high dose rate remote afterloader cancer treatment system, has been given 510(k) clearance for marketing in the US. Frequently used in the treatment of gynaecological and lung cancers, the system employs a catheter and applicators to position a radioactive isotope directly in or next to tumour sites. It is used to administer most treatments on an outpatient basis and can be used to supplement conventional external beam radiotherapy and certain surgical procedures. VariSource is produced at Varian's factory in Crawley in the UK.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.